Gene therapy for retinal and choroidal diseases

Research output: Contribution to journalArticle

Abstract

The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.

Original languageEnglish (US)
Pages (from-to)537-544
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume2
Issue number5
DOIs
StatePublished - 2002

Fingerprint

Choroid Diseases
Gene transfer
Gene therapy
Retinal Diseases
Genetic Therapy
Retinal Degeneration
Genes
Catalytic RNA
Blood
Demonstrations
Leber Congenital Amaurosis
Retinal Neovascularization
Choroidal Neovascularization
Vertebrate Photoreceptor Cells
Blood Circulation
Proteins
Therapeutics
Epithelial Cells
Clinical Trials
Dogs

Keywords

  • Gene therapy
  • Neovascularisation
  • Neurotrophic factors
  • Proliferative retinopathies
  • Retinal degenerations

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Gene therapy for retinal and choroidal diseases. / Campochiaro, Peter A.

In: Expert Opinion on Biological Therapy, Vol. 2, No. 5, 2002, p. 537-544.

Research output: Contribution to journalArticle

@article{e74faa2b0ce745f8bab6625f4ecda28b,
title = "Gene therapy for retinal and choroidal diseases",
abstract = "The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.",
keywords = "Gene therapy, Neovascularisation, Neurotrophic factors, Proliferative retinopathies, Retinal degenerations",
author = "Campochiaro, {Peter A}",
year = "2002",
doi = "10.1517/14712598.2.5.537",
language = "English (US)",
volume = "2",
pages = "537--544",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Gene therapy for retinal and choroidal diseases

AU - Campochiaro, Peter A

PY - 2002

Y1 - 2002

N2 - The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.

AB - The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.

KW - Gene therapy

KW - Neovascularisation

KW - Neurotrophic factors

KW - Proliferative retinopathies

KW - Retinal degenerations

UR - http://www.scopus.com/inward/record.url?scp=0035987409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035987409&partnerID=8YFLogxK

U2 - 10.1517/14712598.2.5.537

DO - 10.1517/14712598.2.5.537

M3 - Article

VL - 2

SP - 537

EP - 544

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -